<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title38.html">
                                    Title 38
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/38CFR4.html">Part 4
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  4.97  Schedule of ratings--respiratory system.------------------------------------------------------------------------
                            </h3>
                            <p class="depth0">Rating------------------------------------------------------------------------</p><p class="depth0">DISEASES OF THE NOSE AND THROAT------------------------------------------------------------------------6502 Septum, nasal, deviation of:</p><p class="depth0">Traumatic only,</p><p class="depth0">With 50-percent obstruction of the nasal passage on           10</p><p class="depth0">both sides or complete obstruction on one side........6504 Nose, loss of part of, or scars:</p><p class="depth0">Exposing both nasal passages...............................       30</p><p class="depth0">Loss of part of one ala, or other obvious disfigurement....       10</p><p class="depth0">Note: Or evaluate as DC 7800, scars, disfiguring, head, face,</p><p class="depth0">or neck.</p><p class="depth0">6510 Sinusitis, pansinusitis, chronic.6511 Sinusitis, ethmoid, chronic.6512 Sinusitis, frontal, chronic.6513 Sinusitis, maxillary, chronic.6514 Sinusitis, sphenoid, chronic.</p><p class="depth0">General Rating Formula for Sinusitis (DC's 6510 through</p><p class="depth0">6514):</p><p class="depth0">Following radical surgery with chronic osteomyelitis,         50</p><p class="depth0">or; near constant sinusitis characterized by</p><p class="depth0">headaches, pain and tenderness of affected sinus, and</p><p class="depth0">purulent discharge or crusting after repeated</p><p class="depth0">surgeries.............................................</p><p class="depth0">Three or more incapacitating episodes per year of             30</p><p class="depth0">sinusitis requiring prolonged (lasting four to six</p><p class="depth0">weeks) antibiotic treatment, or; more than six non-</p><p class="depth0">incapacitating episodes per year of sinusitis</p><p class="depth0">characterized by headaches, pain, and purulent</p><p class="depth0">discharge or crusting.................................</p><p class="depth0">One or two incapacitating episodes per year of                10</p><p class="depth0">sinusitis requiring prolonged (lasting four to six</p><p class="depth0">weeks) antibiotic treatment, or; three to six non-</p><p class="depth0">incapacitating episodes per year of sinusitis</p><p class="depth0">characterized by headaches, pain, and purulent</p><p class="depth0">discharge or crusting.................................</p><p class="depth0">Detected by X-ray only.................................        0</p><p class="depth0">Note: An incapacitating episode of sinusitis means one that</p><p class="depth0">requires bed rest and treatment by a physician.</p><p class="depth0">6515 Laryngitis, tuberculous, active or inactive.</p><p class="depth0">Rate under Sec.  Sec.   4.88c or 4.89, whichever is</p><p class="depth0">appropriate.6516 Laryngitis, chronic:</p><p class="depth0">Hoarseness, with thickening or nodules of cords, polyps,          30</p><p class="depth0">submucous infiltration, or pre-malignant changes on biopsy</p><p class="depth0">Hoarseness, with inflammation of cords or mucous membrane..       106518 Laryngectomy, total.......................................  \1\ 100</p><p class="depth0">Rate the residuals of partial laryngectomy as laryngitis</p><p class="depth0">(DC 6516), aphonia (DC 6519), or stenosis of larynx (DC</p><p class="depth0">6520).6519 Aphonia, complete organic:</p><p class="depth0">Constant inability to communicate by speech................  \1\ 100</p><p class="depth0">Constant inability to speak above a whisper................       60</p><p class="depth0">Note: Evaluate incomplete aphonia as laryngitis, chronic</p><p class="depth0">(DC 6516).</p><p class="depth0">6520 Larynx, stenosis of, including residuals of laryngeal</p><p class="depth0">trauma (unilateral or bilateral):</p><p class="depth0">Forced expiratory volume in one second (FEV-1) less than 40      100</p><p class="depth0">percent of predicted value, with Flow-Volume Loop</p><p class="depth0">compatible with upper airway obstruction, or; permanent</p><p class="depth0">tracheostomy..............................................</p><p class="depth0">FEV-1 of 40- to 55-percent predicted, with Flow-Volume Loop       60</p><p class="depth0">compatible with upper airway obstruction..................</p><p class="depth0">FEV-1 of 56- to 70-percent predicted, with Flow-Volume Loop       30</p><p class="depth0">compatible with upper airway obstruction..................</p><p class="depth0">FEV-1 of 71- to 80-percent predicted, with Flow-Volume Loop       10</p><p class="depth0">compatible with upper airway obstruction..................</p><p class="depth0">Note: Or evaluate as aphonia (DC 6519).</p><p class="depth0">6521 Pharynx, injuries to:</p><p class="depth0">Stricture or obstruction of pharynx or nasopharynx, or;           50</p><p class="depth0">absence of soft palate secondary to trauma, chemical burn,</p><p class="depth0">or granulomatous disease, or; paralysis of soft palate</p><p class="depth0">with swallowing difficulty (nasal regurgitation) and</p><p class="depth0">speech impairment.........................................6522 Allergic or vasomotor rhinitis:</p><p class="depth0">With polyps................................................       30</p><p class="depth0">Without polyps, but with greater than 50-percent                  10</p><p class="depth0">obstruction of nasal passage on both sides or complete</p><p class="depth0">obstruction on one side...................................6523 Bacterial rhinitis:</p><p class="depth0">Rhinoscleroma..............................................       50</p><p class="depth0">With permanent hypertrophy of turbinates and with greater         10</p><p class="depth0">than 50-percent obstruction of nasal passage on both sides</p><p class="depth0">or complete obstruction on one side.......................6524 Granulomatous rhinitis:</p><p class="depth0">Wegener's granulomatosis, lethal midline granuloma.........      100</p><p class="depth0">Other types of granulomatous infection.....................       20------------------------------------------------------------------------</p><p class="depth0">DISEASES OF THE TRACHEA AND BRONCHI------------------------------------------------------------------------6600 Bronchitis, chronic:</p><p class="depth0">FEV-1 less than 40 percent of predicted value, or; the           100</p><p class="depth0">ratio of Forced Expiratory Volume in one second to Forced</p><p class="depth0">Vital Capacity (FEV-1/FVC) less than 40 percent, or;</p><p class="depth0">Diffusion Capacity of the Lung for Carbon Monoxide by the</p><p class="depth0">Single Breath Method (DLCO (SB)) less than 40-percent</p><p class="depth0">predicted, or; maximum exercise capacity less than 15 ml/</p><p class="depth0">kg/min oxygen consumption (with cardiac or respiratory</p><p class="depth0">limitation), or; cor pulmonale (right heart failure), or;</p><p class="depth0">right ventricular hypertrophy, or; pulmonary hypertension</p><p class="depth0">(shown by Echo or cardiac catheterization), or; episode(s)</p><p class="depth0">of acute respiratory failure, or; requires outpatient</p><p class="depth0">oxygen therapy............................................</p><p class="depth0">FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40         60</p><p class="depth0">to 55 percent, or; DLCO (SB) of 40- to 55-percent</p><p class="depth0">predicted, or; maximum oxygen consumption of 15 to 20 ml/</p><p class="depth0">kg/min (with cardiorespiratory limit).....................</p><p class="depth0">FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56         30</p><p class="depth0">to 70 percent, or; DLCO (SB) 56- to 65-percent predicted..</p><p class="depth0">FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71         10</p><p class="depth0">to 80 percent, or; DLCO (SB) 66- to 80-percent predicted..6601 Bronchiectasis:</p><p class="depth0">With incapacitating episodes of infection of at least six        100</p><p class="depth0">weeks total duration per year.............................</p><p class="depth0">With incapacitating episodes of infection of four to six          60</p><p class="depth0">weeks total duration per year, or; near constant findings</p><p class="depth0">of cough with purulent sputum associated with anorexia,</p><p class="depth0">weight loss, and frank hemoptysis and requiring antibiotic</p><p class="depth0">usage almost continuously.................................</p><p class="depth0">With incapacitating episodes of infection of two to four          30</p><p class="depth0">weeks total duration per year, or; daily productive cough</p><p class="depth0">with sputum that is at times purulent or blood-tinged and</p><p class="depth0">that requires prolonged (lasting four to six weeks)</p><p class="depth0">antibiotic usage more than twice a year...................</p><p class="depth0">Intermittent productive cough with acute infection                10</p><p class="depth0">requiring a course of antibiotics at least twice a year...</p><p class="depth0">Or rate according to pulmonary impairment as for chronic</p><p class="depth0">bronchitis (DC 6600).</p><p class="depth0">Note: An incapacitating episode is one that requires</p><p class="depth0">bedrest and treatment by a physician.</p><p class="depth0">6602 Asthma, bronchial:</p><p class="depth0">FEV-1 less than 40-percent predicted, or; FEV-1/FVC less         100</p><p class="depth0">than 40 percent, or; more than one attack per week with</p><p class="depth0">episodes of respiratory failure, or; requires daily use of</p><p class="depth0">systemic (oral or parenteral) high dose corticosteroids or</p><p class="depth0">immuno-suppressive medications............................</p><p class="depth0">FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40         60</p><p class="depth0">to 55 percent, or; at least monthly visits to a physician</p><p class="depth0">for required care of exacerbations, or; intermittent (at</p><p class="depth0">least three per year) courses of systemic (oral or</p><p class="depth0">parenteral) corticosteroids...............................</p><p class="depth0">FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56         30</p><p class="depth0">to 70 percent, or; daily inhalational or oral</p><p class="depth0">bronchodilator therapy, or; inhalational anti-inflammatory</p><p class="depth0">medication................................................</p><p class="depth0">FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71         10</p><p class="depth0">to 80 percent, or; intermittent inhalational or oral</p><p class="depth0">bronchodilator therapy....................................</p><p class="depth0">Note: In the absence of clinical findings of asthma at time</p><p class="depth0">of examination, a verified history of asthmatic attacks</p><p class="depth0">must be of record.</p><p class="depth0">6603 Emphysema, pulmonary:</p><p class="depth0">FEV-1 less than 40 percent of predicted value, or; the           100</p><p class="depth0">ratio of Forced Expiratory Volume in one second to Forced</p><p class="depth0">Vital Capacity (FEV-1/FVC) less than 40 percent, or;</p><p class="depth0">Diffusion Capacity of the Lung for Carbon Monoxide by the</p><p class="depth0">Single Breath Method (DLCO (SB)) less than 40-percent</p><p class="depth0">predicted, or; maximum exercise capacity less than 15 ml/</p><p class="depth0">kg/min oxygen consumption (with cardiac or respiratory</p><p class="depth0">limitation), or; cor pulmonale (right heart failure), or;</p><p class="depth0">right ventricular hypertrophy, or; pulmonary hypertension</p><p class="depth0">(shown by Echo or cardiac catheterization), or; episode(s)</p><p class="depth0">of acute respiratory failure, or; requires outpatient</p><p class="depth0">oxygen therapy............................................</p><p class="depth0">FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40         60</p><p class="depth0">to 55 percent, or; DLCO (SB) of 40- to 55-percent</p><p class="depth0">predicted, or; maximum oxygen consumption of 15 to 20 ml/</p><p class="depth0">kg/min (with cardiorespiratory limit).....................</p><p class="depth0">FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56         30</p><p class="depth0">to 70 percent, or; DLCO (SB) 56- to 65-percent predicted..</p><p class="depth0">FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71         10</p><p class="depth0">to 80 percent, or; DLCO (SB) 66- to 80-percent predicted..6604 Chronic obstructive pulmonary disease:</p><p class="depth0">FEV-1 less than 40 percent of predicted value, or; the           100</p><p class="depth0">ratio of Forced Expiratory Volume in one second to Forced</p><p class="depth0">Vital Capacity (FEV-1/FVC) less than 40 percent, or;</p><p class="depth0">Diffusion Capacity of the Lung for Carbon Monoxide by the</p><p class="depth0">Single Breath Method (DLCO (SB)) less than 40-percent</p><p class="depth0">predicted, or; maximum exercise capacity less than 15 ml/</p><p class="depth0">kg/min oxygen consumption (with cardiac or respiratory</p><p class="depth0">limitation), or; cor pulmonale (right heart failure), or;</p><p class="depth0">right ventricular hypertrophy, or; pulmonary hypertension</p><p class="depth0">(shown by Echo or cardiac catheterization), or; episode(s)</p><p class="depth0">of acute respiratory failure, or; requires outpatient</p><p class="depth0">oxygen therapy............................................</p><p class="depth0">FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40         60</p><p class="depth0">to 55 percent, or; DLCO (SB) of 40- to 55-percent</p><p class="depth0">predicted, or; maximum oxygen consumption of 15 to 20 ml/</p><p class="depth0">kg/min (with cardiorespiratory limit).....................</p><p class="depth0">FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56         30</p><p class="depth0">to 70 percent, or; DLCO (SB) 56- to 65-percent predicted..</p><p class="depth0">FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71         10</p><p class="depth0">to 80 percent, or; DLCO (SB) 66- to 80-percent predicted..------------------------------------------------------------------------</p><p class="depth0">DISEASES OF THE LUNGS AND PLEURA--TUBERCULOSIS</p><p class="depth0">Ratings for Pulmonary Tuberculosis Entitled on August 19, 1968------------------------------------------------------------------------6701 Tuberculosis, pulmonary, chronic, far advanced, active....      1006702 Tuberculosis, pulmonary, chronic, moderately advanced,          100</p><p class="depth0">active........................................................6703 Tuberculosis, pulmonary, chronic, minimal, active.........      1006704 Tuberculosis, pulmonary, chronic, active, advancement           100</p><p class="depth0">unspecified...................................................6721 Tuberculosis, pulmonary, chronic, far advanced, inactive..6722 Tuberculosis, pulmonary, chronic, moderately advanced,</p><p class="depth0">inactive......................................................6723 Tuberculosis, pulmonary, chronic, minimal, inactive.......6724 Tuberculosis, pulmonary, chronic, inactive, advancement</p><p class="depth0">unspecified...................................................</p><p class="depth0">General Rating Formula for Inactive Pulmonary Tuberculosis:      100</p><p class="depth0">For two years after date of inactivity, following active</p><p class="depth0">tuberculosis, which was clinically identified during</p><p class="depth0">service or subsequently...................................</p><p class="depth0">Thereafter for four years, or in any event, to six years          50</p><p class="depth0">after date of inactivity..................................</p><p class="depth0">Thereafter, for five years, or to eleven years after date         30</p><p class="depth0">of inactivity.............................................</p><p class="depth0">Following far advanced lesions diagnosed at any time while        30</p><p class="depth0">the disease process was active, minimum...................</p><p class="depth0">Following moderately advanced lesions, provided there is          20</p><p class="depth0">continued disability, emphysema, dyspnea on exertion,</p><p class="depth0">impairment of health, etc.................................</p><p class="depth0">Otherwise..................................................        0</p><p class="depth0">Note (1): The 100-percent rating under codes 6701 through 6724</p><p class="depth0">is not subject to a requirement of precedent hospital</p><p class="depth0">treatment. It will be reduced to 50 percent for failure to</p><p class="depth0">submit to examination or to follow prescribed treatment upon</p><p class="depth0">report to that effect from the medical authorities. When a</p><p class="depth0">veteran is placed on the 100-percent rating for inactive</p><p class="depth0">tuberculosis, the medical authorities will be appropriately</p><p class="depth0">notified of the fact, and of the necessity, as given in</p><p class="depth0">footnote 1 to 38 U.S.C. 1156 (and formerly in 38 U.S.C. 356,</p><p class="depth0">which has been repealed by Public Law 90-493), to notify the</p><p class="depth0">Veterans Service Center in the event of failure to submit to</p><p class="depth0">examination or to follow treatment.Note (2): The graduated 50-percent and 30-percent ratings and</p><p class="depth0">the permanent 30 percent and 20 percent ratings for inactive</p><p class="depth0">pulmonary tuberculosis are not to be combined with ratings for</p><p class="depth0">other respiratory disabilities. Following thoracoplasty the</p><p class="depth0">rating will be for removal of ribs combined with the rating</p><p class="depth0">for collapsed lung. Resection of the ribs incident to</p><p class="depth0">thoracoplasty will be rated as removal.------------------------------------------------------------------------</p><p class="depth0">Ratings for Pulmonary Tuberculosis Initially Evaluated After August 19,</p><p class="depth0">1968------------------------------------------------------------------------6730 Tuberculosis, pulmonary, chronic, active..................      100</p><p class="depth0">Note: Active pulmonary tuberculosis will be considered</p><p class="depth0">permanently and totally disabling for non-service-</p><p class="depth0">connected pension purposes in the following circumstances:</p><p class="depth0"><em>(a)</em> Associated with active tuberculosis involving other</p><p class="depth0">than the respiratory system.</p><p class="depth0"><em>(b)</em> With severe associated symptoms or with extensive</p><p class="depth0">cavity formation.</p><p class="depth0"><em>(c)</em> Reactivated cases, generally.</p><p class="depth0"><em>(d)</em> With advancement of lesions on successive</p><p class="depth0">examinations or while under treatment.</p><p class="depth0"><em>(e)</em> Without retrogression of lesions or other evidence</p><p class="depth0">of material improvement at the end of six months</p><p class="depth0">hospitalization or without change of diagnosis from</p><p class="depth0">``active'' at the end of 12 months hospitalization.</p><p class="depth0">Material improvement means lessening or absence of</p><p class="depth0">clinical symptoms, and X-ray findings of a stationary</p><p class="depth0">or retrogressive lesion.</p><p class="depth0">6731 Tuberculosis, pulmonary, chronic, inactive:</p><p class="depth0">Depending on the specific findings, rate residuals as</p><p class="depth0">interstitial lung disease, restrictive lung disease, or,</p><p class="depth0">when obstructive lung disease is the major residual, as</p><p class="depth0">chronic bronchitis (DC 6600). Rate thoracoplasty as</p><p class="depth0">removal of ribs under DC 5297.</p><p class="depth0">Note: A mandatory examination will be requested immediately</p><p class="depth0">following notification that active tuberculosis evaluated</p><p class="depth0">under DC 6730 has become inactive. Any change in</p><p class="depth0">evaluation will be carried out under the provisions of</p><p class="depth0">Sec.   3.105(e).</p><p class="depth0">6732 Pleurisy, tuberculous, active or inactive:</p><p class="depth0">Rate under Sec.  Sec.   4.88c or 4.89, whichever is</p><p class="depth0">appropriate.------------------------------------------------------------------------</p><p class="depth0">NONTUBERCULOUS DISEASES------------------------------------------------------------------------6817 Pulmonary Vascular Disease:</p><p class="depth0">Primary pulmonary hypertension, or; chronic pulmonary            100</p><p class="depth0">thromboembolism with evidence of pulmonary hypertension,</p><p class="depth0">right ventricular hypertrophy, or cor pulmonale, or;</p><p class="depth0">pulmonary hypertension secondary to other obstructive</p><p class="depth0">disease of pulmonary arteries or veins with evidence of</p><p class="depth0">right ventricular hypertrophy or cor pulmonale............</p><p class="depth0">Chronic pulmonary thromboembolism requiring anticoagulant         60</p><p class="depth0">therapy, or; following inferior vena cava surgery without</p><p class="depth0">evidence of pulmonary hypertension or right ventricular</p><p class="depth0">dysfunction...............................................</p><p class="depth0">Symptomatic, following resolution of acute pulmonary              30</p><p class="depth0">embolism..................................................</p><p class="depth0">Asymptomatic, following resolution of pulmonary                    0</p><p class="depth0">thromboembolism...........................................</p><p class="depth0">Note: Evaluate other residuals following pulmonary embolism</p><p class="depth0">under the most appropriate diagnostic code, such as</p><p class="depth0">chronic bronchitis (DC 6600) or chronic pleural effusion</p><p class="depth0">or fibrosis (DC 6844), but do not combine that evaluation</p><p class="depth0">with any of the above evaluations.</p><p class="depth0">6819 Neoplasms, malignant, any specified part of                 100</p><p class="depth0">respiratory system exclusive of skin growths..............</p><p class="depth0">Note: A rating of 100 percent shall continue beyond the</p><p class="depth0">cessation of any surgical, X-ray, antineoplastic</p><p class="depth0">chemotherapy or other therapeutic procedure. Six months</p><p class="depth0">after discontinuance of such treatment, the appropriate</p><p class="depth0">disability rating shall be determined by mandatory VA</p><p class="depth0">examination. Any change in evaluation based upon that or</p><p class="depth0">any subsequent examination shall be subject to the</p><p class="depth0">provisions of Sec.   3.105(e) of this chapter. If there</p><p class="depth0">has been no local recurrence or metastasis, rate on</p><p class="depth0">residuals.</p><p class="depth0">6820 Neoplasms, benign, any specified part of respiratory</p><p class="depth0">system. Evaluate using an appropriate respiratory analogy.------------------------------------------------------------------------</p><p class="depth0">Bacterial Infections of the Lung------------------------------------------------------------------------6822 Actinomycosis.6823 Nocardiosis.6824 Chronic lung abscess.</p><p class="depth0">General Rating Formula for Bacterial Infections of the Lung</p><p class="depth0">(diagnostic codes 6822 through 6824):</p><p class="depth0">Active infection with systemic symptoms such as fever,       100</p><p class="depth0">night sweats, weight loss, or hemoptysis..............</p><p class="depth0">Depending on the specific findings, rate residuals as</p><p class="depth0">interstitial lung disease, restrictive lung disease, or,</p><p class="depth0">when obstructive lung disease is the major residual, as</p><p class="depth0">chronic bronchitis (DC 6600).------------------------------------------------------------------------</p><p class="depth0">Interstitial Lung Disease------------------------------------------------------------------------6825 Diffuse interstitial fibrosis (interstitial pneumonitis,</p><p class="depth0">fibrosing alveolitis).6826 Desquamative interstitial pneumonitis.6827 Pulmonary alveolar proteinosis.6828 Eosinophilic granuloma of lung.</p><p class="depth0">6829 Drug-induced pulmonary pneumonitis and fibrosis.6830 Radiation-induced pulmonary pneumonitis and fibrosis.6831 Hypersensitivity pneumonitis (extrinsic allergic</p><p class="depth0">alveolitis).6832 Pneumoconiosis (silicosis, anthracosis, etc.).6833 Asbestosis.</p><p class="depth0">General Rating Formula for Interstitial Lung Disease</p><p class="depth0">(diagnostic codes 6825 through 6833):</p><p class="depth0">Forced Vital Capacity (FVC) less than 50-percent             100</p><p class="depth0">predicted, or; Diffusion Capacity of the Lung for</p><p class="depth0">Carbon Monoxide by the Single Breath Method (DLCO</p><p class="depth0"><em>(SB))</em> less than 40-percent predicted, or; maximum</p><p class="depth0">exercise capacity less than 15 ml/kg/min oxygen</p><p class="depth0">consumption with cardiorespiratory limitation, or; cor</p><p class="depth0">pulmonale or pulmonary hypertension, or; requires</p><p class="depth0">outpatient oxygen therapy.............................</p><p class="depth0">FVC of 50- to 64-percent predicted, or; DLCO (SB) of 40-      60</p><p class="depth0">to 55-percent predicted, or; maximum exercise</p><p class="depth0">capacity of 15 to 20 ml/kg/min oxygen consumption with</p><p class="depth0">cardiorespiratory limitation..........................</p><p class="depth0">FVC of 65- to 74-percent predicted, or; DLCO (SB) of 56-      30</p><p class="depth0">to 65-percent predicted..............................</p><p class="depth0">FVC of 75- to 80-percent predicted, or; DLCO (SB) of 66-      10</p><p class="depth0">to 80-percent predicted..............................------------------------------------------------------------------------</p><p class="depth0">Mycotic Lung Disease------------------------------------------------------------------------6834 Histoplasmosis of lung.6835 Coccidioidomycosis.6836 Blastomycosis.6837 Cryptococcosis.6838 Aspergillosis.6839 Mucormycosis.</p><p class="depth0">General Rating Formula for Mycotic Lung Disease (diagnostic</p><p class="depth0">codes 6834 through 6839):</p><p class="depth0">Chronic pulmonary mycosis with persistent fever, weight      100</p><p class="depth0">loss, night sweats, or massive hemoptysis.............</p><p class="depth0">Chronic pulmonary mycosis requiring suppressive therapy       50</p><p class="depth0">with no more than minimal symptoms such as occasional</p><p class="depth0">minor hemoptysis or productive cough..................</p><p class="depth0">Chronic pulmonary mycosis with minimal symptoms such as       30</p><p class="depth0">occasional minor hemoptysis or productive cough.......</p><p class="depth0">Healed and inactive mycotic lesions, asymptomatic......        0</p><p class="depth0">Note: Coccidioidomycosis has an incubation period up to 21</p><p class="depth0">days, and the disseminated phase is ordinarily manifest</p><p class="depth0">within six months of the primary phase. However, there are</p><p class="depth0">instances of dissemination delayed up to many years after</p><p class="depth0">the initial infection which may have been unrecognized.</p><p class="depth0">Accordingly, when service connection is under</p><p class="depth0">consideration in the absence of record or other evidence</p><p class="depth0">of the disease in service, service in southwestern United</p><p class="depth0">States where the disease is endemic and absence of</p><p class="depth0">prolonged residence in this locality before or after</p><p class="depth0">service will be the deciding factor.------------------------------------------------------------------------</p><p class="depth0">Restrictive Lung Disease------------------------------------------------------------------------6840 Diaphragm paralysis or paresis.6841 Spinal cord injury with respiratory insufficiency.6842 Kyphoscoliosis, pectus excavatum, pectus carinatum.6843 Traumatic chest wall defect, pneumothorax, hernia, etc.6844 Post-surgical residual (lobectomy, pneumonectomy, etc.).6845 Chronic pleural effusion or fibrosis.</p><p class="depth0">General Rating Formula for Restrictive Lung Disease</p><p class="depth0">(diagnostic codes 6840 through 6845):</p><p class="depth0">FEV-1 less than 40 percent of predicted value, or; the       100</p><p class="depth0">ratio of Forced Expiratory Volume in one second to</p><p class="depth0">Forced Vital Capacity (FEV-1/FVC) less than 40</p><p class="depth0">percent, or; Diffusion Capacity of the Lung for Carbon</p><p class="depth0">Monoxide by the Single Breath Method (DLCO (SB)) less</p><p class="depth0">than 40-percent predicted, or; maximum exercise</p><p class="depth0">capacity less than 15 ml/kg/min oxygen consumption</p><p class="depth0">(with cardiac or respiratory limitation), or; cor</p><p class="depth0">pulmonale (right heart failure), or; right ventricular</p><p class="depth0">hypertrophy, or; pulmonary hypertension (shown by Echo</p><p class="depth0">or cardiac catheterization), or; episode(s) of acute</p><p class="depth0">respiratory failure, or; requires outpatient oxygen</p><p class="depth0">therapy...............................................</p><p class="depth0">FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of        60</p><p class="depth0">40 to 55 percent, or; DLCO (SB) of 40- to 55-percent</p><p class="depth0">predicted, or; maximum oxygen consumption of 15 to 20</p><p class="depth0">ml/kg/min (with cardiorespiratory limit)..............</p><p class="depth0">FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of        30</p><p class="depth0">56 to 70 percent, or; DLCO (SB) 56- to 65-percent</p><p class="depth0">predicted.............................................</p><p class="depth0">FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of        10</p><p class="depth0">71 to 80 percent, or; DLCO (SB) 66- to 80-percent</p><p class="depth0">predicted.............................................</p><p class="depth0">Or rate primary disorder.</p><p class="depth0">Note (1): A 100-percent rating shall be assigned for</p><p class="depth0">pleurisy with empyema, with or without pleurocutaneous</p><p class="depth0">fistula, until resolved.</p><p class="depth0">Note (2): Following episodes of total spontaneous</p><p class="depth0">pneumothorax, a rating of 100 percent shall be assigned as</p><p class="depth0">of the date of hospital admission and shall continue for</p><p class="depth0">three months from the first day of the month after</p><p class="depth0">hospital discharge.</p><p class="depth0">Note (3): Gunshot wounds of the pleural cavity with bullet</p><p class="depth0">or missile retained in lung, pain or discomfort on</p><p class="depth0">exertion, or with scattered rales or some limitation of</p><p class="depth0">excursion of diaphragm or of lower chest expansion shall</p><p class="depth0">be rated at least 20-percent disabling. Disabling injuries</p><p class="depth0">of shoulder girdle muscles (Groups I to IV) shall be</p><p class="depth0">separately rated and combined with ratings for respiratory</p><p class="depth0">involvement. Involvement of Muscle Group XXI (DC 5321),</p><p class="depth0">however, will not be separately rated.</p><p class="depth0">6846 Sarcoidosis:</p><p class="depth0">Cor pulmonale, or; cardiac involvement with congestive           100</p><p class="depth0">heart failure, or; progressive pulmonary disease with</p><p class="depth0">fever, night sweats, and weight loss despite treatment....</p><p class="depth0">Pulmonary involvement requiring systemic high dose                60</p><p class="depth0"><em>(therapeutic)</em> corticosteroids for control.................</p><p class="depth0">Pulmonary involvement with persistent symptoms requiring          30</p><p class="depth0">chronic low dose (maintenance) or intermittent</p><p class="depth0">corticosteroids...........................................</p><p class="depth0">Chronic hilar adenopathy or stable lung infiltrates without        0</p><p class="depth0">symptoms or physiologic impairment........................</p><p class="depth0">Or rate active disease or residuals as chronic bronchitis</p><p class="depth0">(DC 6600) and extra-pulmonary involvement under specific</p><p class="depth0">body system involved......................................6847 Sleep Apnea Syndromes (Obstructive, Central, Mixed):</p><p class="depth0">Chronic respiratory failure with carbon dioxide retention        100</p><p class="depth0">or cor pulmonale, or; requires tracheostomy...............</p><p class="depth0">Requires use of breathing assistance device such as               50</p><p class="depth0">continuous airway pressure (CPAP) machine.................</p><p class="depth0">Persistent day-time hypersomnolence........................       30</p><p class="depth0">Asymptomatic but with documented sleep disorder breathing..       0------------------------------------------------------------------------\1\ Review for entitlement to special monthly compensation under Sec.</p><p class="depth0">3.350 of this chapter.

[61 FR 46728, Sept. 5, 1996, as amended at 71 FR 28586, May 17, 2006]</p><p class="depth0">The Cardiovascular System</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
